Cagrilintide
A long-acting amylin-receptor agonist studied for weight management, both alone and combined with semaglutide as CagriSema.
Not currently stocked by KYIN Peptides, but available to order — see availability below.
What Is Cagrilintide?
Cagrilintide is a synthetic amylin analog developed by Novo Nordisk, using the same fatty-acid acylation technology as semaglutide to extend its half-life for once-weekly subcutaneous dosing. Amylin is a hormone co-secreted with insulin by pancreatic beta cells, and it acts on amylin receptors in the area postrema of the brainstem — a mechanism distinct from, and studied as complementary to, the GLP-1 receptor agonism used by Retatrutide and other incretin-based compounds. Because amylin and GLP-1 signal through separate receptor systems, the two are studied together for potential additive effects on appetite and food intake.
Common Research Applications
- Amylin-receptor agonism and appetite-regulation research
- Monotherapy weight-management research
- Combination research with GLP-1 receptor agonists (as CagriSema, with semaglutide)
Read our Weight Loss & Metabolic research overview →
Clinical & Preclinical Trial Data
As monotherapy, a Phase 2 dose-finding trial (Lau et al., The Lancet, 2021; 706 adults with overweight or obesity, 26 weeks, doses from 0.3mg to 4.5mg weekly) found the highest dose produced a mean weight reduction of 10.8%, compared to 3.0% with placebo and 9.0% with liraglutide 3.0mg as an active comparator.
Combined with semaglutide as CagriSema, the Phase 3 REDEFINE program has reported considerably larger effects: in the REDEFINE-1 trial, participants lost an average of approximately 23% of body weight under the trial's treatment-policy estimand (the effect if all participants remained on treatment). Novo Nordisk has filed a New Drug Application (NDA) for CagriSema with the FDA, with a decision expected later in 2026. As of this writing, neither cagrilintide alone nor CagriSema has received FDA approval.
Availability
Cagrilintide is not part of KYIN Peptides' standard catalogue, but it is available to order — contact us directly and we'll source it for you.
Cagrilintide questions
What is Cagrilintide?
Cagrilintide is a long-acting amylin-receptor agonist developed by Novo Nordisk, using the same fatty-acid acylation technology as semaglutide to extend its half-life for once-weekly dosing. It acts on amylin receptors in the area postrema, a mechanism distinct from and complementary to GLP-1 receptor agonists.
Is Cagrilintide FDA-approved?
No. Cagrilintide is not FDA-approved on its own. Novo Nordisk has filed a New Drug Application (NDA) for CagriSema, the fixed-dose combination of cagrilintide and semaglutide, with an FDA decision expected later in 2026 — but as of this writing, neither cagrilintide alone nor CagriSema has been approved.
What is CagriSema?
CagriSema is Novo Nordisk's fixed-dose combination of cagrilintide and semaglutide, pairing an amylin-receptor agonist with a GLP-1 receptor agonist for an additive effect on appetite and weight. In the Phase 3 REDEFINE-1 trial, participants lost an average of approximately 23% body weight under the trial's treatment-policy estimand.
Does KYIN Peptides sell Cagrilintide?
Not as part of our standard catalogue, but yes — it's available to order. Contact us directly and we'll source it for you.
Interested in sourcing Cagrilintide?
Contact us and we'll help you source it, or browse our stocked weight-loss peptides.